Atriva
is a Germany-based biopharmaceutical company that researches and develops antiviral therapeutics for the treatment of influenza and COVID-19... Read moreAtriva
is a Germany-based biopharmaceutical company that researches and develops antiviral therapeutics for the treatment of influenza and COVID-19... Read more
News
Jun 10, 2024
Pharmabiz
Atriva: Atriva gets US patent for MEK inhibitor zapnometinib, a firstinclass broad spectrum therapy for severe RNA virus infections including bird flu
Oct 04, 2023
B3C Group
Press Release: Atriva : Atriva Therapeutics Announces Publication of Proof of Concept (POC) / Phase 2a RESPIRE Study Data with Zapnometinib in Patients Hospitalized with COVID-19
Sep 18, 2023
Marketscreener
Atriva: Atriva Therapeutics Announces Exclusive Letter Agreement for Reverse Takeover Transaction with Biocure Technology
Nov 09, 2022
centralcharts
Press Release: Atriva : EQS-News: Atriva Therapeutics appoints Christian Pangratz as CEO, implementing planned management change
Nov 09, 2022
centralcharts
Atriva: Atriva Therapeutics appoints Christian Pangratz as CEO, implementing planned management change
Oct 18, 2022
centralcharts
Press Release: Atriva : EQS-News: Atriva Therapeutics announces appointment of CSO and senior leaders to Clinical Development Team
Sep 20, 2022
centralcharts
Press Release: Atriva : EQS-News: Atriva Therapeutics announces Topline Results from the Proof of Concept (POC) / Phase 2a RESPIRE study (zapnometinib) in patients hospitalized with COVID-19
Mar 28, 2022
centralcharts
Press Release: Atriva : DGAP-News: Atriva Therapeutics announces efficacy of its lead compound zapnometinib against Omicron
Jan 10, 2022
MarketScreener
Atriva: Atriva receives FDA Orphan Drug Designation for Zapnometinib to treat Hantavirus Infections
Dec 20, 2021
MarketScreener
Atriva: Atriva Therapeutics to take part in upcoming scientific and industry conferences in early 2022
Atriva Competitors
1
2
3
4
5
6
7
8
9
10